The Trump administration appears poised to extend a temporary, Covid-era rule allowing health providers to prescribe certain controlled substances, like ADHD medications and treatments for opioid addiction, via telemedicine. This extension is significant as it continues to shape the landscape of mental health and addiction treatment in the United States.
Under the current rules, providers can initiate prescriptions for drugs like Ritalin or Adderall for ADHD, or buprenorphine for opioid use disorder, without first examining the patient in-person. This regulatory flexibility has been crucial during the pandemic, enabling greater access to essential medications for vulnerable populations who may otherwise face barriers to care.
As the healthcare community navigates the ongoing implications of these policies, the extension raises questions about the long-term integration of telemedicine in prescribing practices. Stakeholders in regulatory, QA/QC, and sourcing sectors must prepare for potential shifts in compliance and quality assurance standards as these rules evolve.
Use the database as your supply chain compass →
